Caladrius Biosciences (CLBS) Reports Q3 Loss Per Share of $1.33

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. EXPE
3. ARM
4. FIS
5. BROS
6. QCOM
7. DDOG
8. EW
9. ZG
10. W

Go back to Caladrius Biosciences (CLBS) Reports Q3 Loss Per Share of $1.33

Caladrius Biosciences Reports 2016 Second Quarter Financial Results

August 9, 2016 4:09 PM EDT

Total Quarterly Revenues Increase 41% and Expenses Decrease 50% versus Prior Year

Conference Call Begins Today at 5:00 pm Eastern Time

BASKING RIDGE, N.J., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ: CLBS) (Caladrius or the Company), a cell therapy company combining an industry-leading development and manufacturing services provider through its subsidiary PCT, LLC a Caladrius Company (PCT) with a select therapeutic development pipeline, announces financial results for the three and six months ended June 30, 2016.

Business highlights for the second quarter and recent weeks include:

... More